Biography

Dr. Kyrillus Shohdy has completed a bachelor’s degree in medicine, Cairo University, with the highest honors in the top 1% class rank. He has spent three years in a residency program in clinical oncology at Cairo University Hospitals. During this training, Dr. Shohdy was able to get a master’s degree with distinction in clinical oncology and passed the MRCP diploma part 1 and 2, achieving 100% in the oncology subsection. He was keen to enroll in the Clinical Scholars Research Training-United Kingdom (CSRT-UK) Program from Harvard Medical School and University College London, which provided him with training to conduct clinical trials. Dr. Shohdy was able to obtain a full scholarship to the Online Master Study Program “Advanced Oncology” of Ulm University-Germany, which he completed with the highest honors. Under Dr. Faltas mentoring, Kyrillus obtained the prestigious Long-Term International fellowship (LIFe award) from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). The award funded his training and research at Weill Cornell Medical College. Dr. Shohdy was keen to participate in many research projects and was able to publish his work in the Journal of Clinical Oncology, JAMA Oncology, Nature Communications, and npj Genomic Medicine. Recently, Kyrillus achieved the full mark in Genetics/Tumor Biology subsection in the 2021 ASCO Medical Oncology Exam.

He is currently working on understanding the rationale for co-targeting FGFR3 and CDK4/6 pathways in advanced urothelial carcinoma. Also, initiated a window-of-opportunity trial of abemaciclib followed by radical cystectomy in patients with platinum-ineligible urothelial carcinoma to evaluate CDK4/6-dependent phosphorylation of pocket proteins and clonal evolution dynamics (NCT03837821). Dr. Shohdy led a study investigating the true prevalence of deleterious germline variants in urothelial cancer patients using whole-exome sequencing and a novel bioinformatic framework that prioritizes truncating mutations in tumor suppressor genes. Kyrillus obtained the 2021 ESO Clinical Training Centres Fellowship Programme from the European School of Oncology to join the Experimental Cancer Medicine Unit at the Christie NHS Foundation Trust as a lead clinical co-investigator.